Biotherapy of cancer - Perspectives of immunotherapy and gene therapy
Journal of Cancer Research and Clinical Oncology, ISSN: 0171-5216, Vol: 121, Issue: 8, Page: 443-451
1995
- 12Citations
- 12Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations12
- Citation Indexes12
- 12
- CrossRef8
- Captures12
- Readers12
- 11
Review Description
Prospects for a new biologically based strategy of cancer treatment are being discussed. While physically and chemically based therapies, such as radio- and chemotherapy, are not directed against cancer tissue only and have a suppressive effect on the immune system, immunotherapy and gene therapy, which are discussed here, try to be more selective and to stimulate rather than suppress antitumor immune mechanisms. On the basis of personal experience with these new technologies, good future prospects are predicted for the application of cancer vaccines and immune T lymphocytes for active specific immunization (ASI) and adoptive immunotherapy (ADI) respectively. While ASI strategies aim at micrometastases being affected by activated host immune T cells, and might find a place for postoperative adjuvant treatment in high-risk cancer patients, cellular therapies such as ADI do not require an intact host immune system and could therefore also find application in advanced stages of disease. In spite of the exciting new perspectives of immuno- and gene therapy for the cancer patient, this therapy is not yet a defined discipline and requires years of further research. © 1995 Springer-Verlag.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0029117731&origin=inward; http://dx.doi.org/10.1007/bf01218359; http://www.ncbi.nlm.nih.gov/pubmed/7642685; http://link.springer.com/10.1007/BF01218359; http://www.springerlink.com/index/pdf/10.1007/BF01218359; https://dx.doi.org/10.1007/bf01218359; https://link.springer.com/article/10.1007/BF01218359; http://www.springerlink.com/index/10.1007/BF01218359
Springer Nature
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know